Decreased Risk of Fragility Fractures associated with Statin Use in the Older Japanese Population: a Nationwide Case–crossover Study

Iihara, Naomi; Ohara, Eri; Baba, Kanako; Nagao, Soichiro; Bando, Yoshinori; Yoshida, Tomoji; Ohara, Masaki; Kirino, Yutaka

doi:10.1248/bpbreports.2.3_35

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study examined the association between seasonality and incident fracture at different sites [ 8 ]. Using a case-crossover study design, incident fragility fracture, the associations of statin use with fragility fracture, and the associations of central nervous system agents with fragility fracture have been reported [ 9 – 12 ]. The studies examining the testing rates of bone mineral density and pharmacotherapy after hip or vertebral fracture and persistence to pharmacotherapy for osteoporosis have been presented [ 14 , 15 ].…”

Section: Discussionmentioning

confidence: 99%

Medical expenditures for fragility hip fracture in Japan: a study using the nationwide health insurance claims database

et al. 2022

View full text Add to dashboard Cite

Summary Using the nationwide health insurance claims database in Japan, we estimated total annual medical expenditures for fragility hip fracture across the population at 329.2 billion yen (2.99 billion US dollars). Long-term care expenditures were not included. Fragility hip fracture imposes a considerable health economic burden on society in Japan. Purpose Fragility hip fracture imposes a substantial health economic burden on society globally. We aimed to estimate medical expenditures for fragility hip fracture using the nationwide health insurance claims database in Japan. Methods We included adults aged 60 and over without prior hip fracture who were admitted for fragility hip fracture (i.e., femoral neck or extracapsular) between October 2014 and October 2015 (13 months). Fragility hip fracture was identified through newly assigned disease codes for fracture and procedure codes associated with the fracture. As a proxy for medical expenditures per patient, incremental payments were calculated (i.e., the difference between the total payments 6 months before and after fragility hip fracture). The total payments included health insurance reimbursements and copayments for inpatient and outpatient services. Long-term care expenditures were not included in this study. Results We identified 142,361 individuals (28,868 male and 113,493 female) with fragility hip fracture. Mean medical expenditures for fragility hip fracture per patient were 2,550,000 yen (¥) (23,180 US dollars [$]; ¥110 = $1) in male and ¥2,494,000 ($22,670) in female patients, respectively. Total annual medical expenditures for fragility hip fracture across the population were 329.2 billion yen (2.99 billion US dollars): 67.96 billion yen (620 million US dollars) in male and 261.24 billion yen (2.37 billion US dollars) in female patients, respectively. Conclusion This is the first study to estimate medical expenditures for hip fracture using the nationwide health insurance claims database, which represents almost all health insurance claims in Japan. Fragility hip fracture inflicts a considerable health economic burden on society in Japan.

show abstract